Mesenchymal stem cells and uses therefor
US-10960025-B2 · Mar 30, 2021 · US
Mesenchymal stem cells and uses therefor
US11389484B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11389484-B2 |
| Application number | US-201816214485-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2018 |
| Priority date | Mar 22, 2004 |
| Publication date | Jul 19, 2022 |
| Grant date | Jul 19, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an allergic disease or disorder in a human, said method comprising administering mesenchymal stem cells to the human in an amount effective to treat the allergic disease or disorder. 2. The method of claim 1 , wherein the mesenchymal stem cells are genetically unmanipulated. 3. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic. 4. The method of claim 2 , wherein the mesenchymal stem cells are allogeneic. 5. The method of claim 1 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis. 6. The method of claim 2 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis. 7. The method of claim 3 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis. 8. The method of claim 4 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis. 9. The method of claim 1 , wherein the mesenchymal stem cells are administered systemically. 10. The method of claim 1 , wherein the mesenchymal stem cells are administered intravenously or intraarterially. 11. The method of claim 5 , wherein the mesenchymal stem cells are administered intravenously or intraarterially. 12. The method of claim 1 , wherein the mesenchymal stem cells are cultured. 13. The method of claim 5 , wherein the mesenchymal stem cells are cultured. 14. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount from about 1×10 5 cells/kg to about 1×10 7 cells/kg. 15. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount from about 1×10 6 cells/kg to about 5×10 6 cells/kg. 16. The method of claim 1 , wherein the mesenchymal stem cells were isolated from marrow. 17. The method of claim 16 , wherein the marrow is iliac crest marrow. 18. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium. 19. A method of treating asthma in an human, said method comprising intravenously or intraarterially administering genetically unmanipulated allogeneic cultured mesenchymal stem cells to the human in an amount effective to treat the asthma.
Assignees
Inventors
Classifications
IL-10 · CPC title
Drugs for disorders of the respiratory system · CPC title
the cells being hematopoietic, bone marrow derived or blood cells · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Mesenchymal stem cells from hair follicles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11389484B2 cover?
- Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
- Who is the assignee on this patent?
- Mesoblast Int Sarl
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).